Page 90 - 《中国药房》2023年14期
P. 90
度普利尤单抗致眼部相关不良反应文献分析
Δ
＊
付子仪 ，谢婷婷 ，郭代红（解放军总医院医疗保障中心药剂科，北京 100853）
#
中图分类号 R969.3 文献标志码 A 文章编号 1001-0408（2023）14-1744-04
DOI 10.6039/j.issn.1001-0408.2023.14.16
摘 要 目的 分析度普利尤单抗致眼部相关不良反应（ADR）的临床表现和特点，为临床安全用药提供参考。方法 检索中国知
网、万方数据、维普网、PubMed，收集度普利尤单抗致眼部相关ADR的案例报道，对报告涉及的患者性别、年龄、原患疾病、用药情
况、ADR发生时间、主要临床表现、治疗及转归等进行统计分析。结果 共纳入文献20篇，涉及患者46例，其中男性29例，女性17
例，年龄以 60 岁以下为主。关联性评价结果为“很可能”13 例、“可能”33 例。所有患者均为使用度普利尤单抗治疗特应性皮炎
（AD），无超适应证用药情况。ADR发生时间为用药后2周～2年，以用药后6个月内为主；除3例合并高血压、1例合并慢性阻塞
性肺疾病及人类免疫缺陷病毒感染患者同时使用了其他药物外，其余患者均为单用度普利尤单抗。有 28 例患者有过敏性疾病
史，11例有眼部疾病史；眼部相关ADR以结膜炎、葡萄膜炎为主，临床表现主要为结膜充血、肿胀、眼部分泌物等；10例患者发生严
重的ADR，包括葡萄膜炎、严重程度的结膜炎及泪点狭窄。45例患者经对症治疗后好转。AD、AD初始症状较重、有过敏性疾病
史及眼部基础疾病史可能是度普利尤单抗致眼部相关ADR的高危因素。结论 临床使用度普利尤单抗前应详细询问患者的过敏
性疾病史和眼部基础疾病史，使用时应注意监测患者是否有发生眼内炎症的风险，同时警惕新的、严重的 ADR 发生，一旦发生
ADR应及时给予对症治疗，以保障患者用药安全。
关键词 度普利尤单抗；视网膜炎；葡萄膜炎；眼部不良反应；文献分析
Literature analysis of ocular adverse drug reactions related to dupilumab
FU Ziyi，XIE Tingting，GUO Daihong（Dept. of Pharmacy， Medical Supplies Center of PLA General Hospital，
Beijing 100853， China）
ABSTRACT OBJECTIVE To analyze the clinical manifestation and characteristics of ocular adverse drug reaction （ADR）
related to dupilumab， so as to provide reference for clinically safe drug use. METHODS Retrieved from CNKI， Wanfang data，
VIP and PubMed databases， the case reports about ocular ADR caused by dupilumab were collected， and then analyzed statistically
in terms of gender， age， primary disease， drug use， occurrence time of ADR， main clinical manifestations， treatment or outcome，
etc. RESULTS A total of 20 pieces of literature were selected， involving 46 patients， among which there were 29 males and 17
females. Mainly patients were under 60 years old. The results of the association evaluation was given as follows： 13 were “very
likely” and 33 were “likely”. All patients were treated with dupilumab for atopic dermatitis （AD） without off-label medication. The
occurrence time of ADR was 2 weeks to 2 years after administration， mainly within 6 months after medication. All patients received
dupilumab monotherapy except that 3 patients with hypertension and 1 patient with chronic obstructive pulmonary disease and
human immunodeficiency virus received other drugs simultaneously. Twenty-eight patients had a history of allergic disease， and 11
patients had a history of eye disease. Ocular ADRs were mainly conjunctivitis and uveitis， and the clinical manifestations mainly
included conjunctival congestion， swelling， eye secretions， etc. Ten patients developed severe ADR， including uveitis， severe
conjunctivitis， and tear point stenosis； 45 patients were improved after symptomatic treatment. AD， serious initial symptoms of
AD， allergic disease and underlying ocular diseases might be the high-risk factors of ocular ADR caused by dupilumab.
CONCLUSIONS Whether the patient has the history of allergic diseases and basic eye diseases should be asked in detail before
clinical use of dupilumab. When using the drug， attention should be paid to monitoring whether the patient has intraocular
inflammation， be alert to the occurrence of new or serious ADR， and give timely symptomatic treatment to ensure the safety of
drug use.
KEYWORDS dupilumab； retinitis； uveitis； ocular adverse drug reaction； literature analysis
Δ 基金项目 中国研究型医院学会科研课题-临床重点药品的使用 特应性皮炎（atopic dermatitis，AD）是一种常见的慢
监测和评价研究专项（No.Y2023FH-YWPJ03） 性炎症性皮肤病，以湿疹样皮损、干燥及瘙痒等为主要
＊第一作者 药师。研究方向：临床药学与药物警戒。E-mail：
表现。AD的发病机制尚不明确，有研究认为，辅助型T
1250465249@qq.com
细胞 2（T helper 2 cell，Th2）分泌的白细胞介素 4（inter‐
# 通信作者 副主任药师，硕士。研究方向：临床药学。电话：010-
66937047。E-mail：tingting82416@163.com leukin-4，IL-4）和 IL-13 是介导 AD 发病的重要细胞因
· 1744 · China Pharmacy 2023 Vol. 34 No. 14 中国药房 2023年第34卷第14期
